Dean Wang1, Christopher L Camp2, Anil S Ranawat1, Struan H Coleman1, Bryan T Kelly1, Brian C Werner3. 1. Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York, U.S.A. 2. Sports Medicine and Shoulder Service, Hospital for Special Surgery, New York, New York, U.S.A.; Department of Orthopedics, Mayo Clinic Sports Medicine Center, Rochester, Minnesota, U.S.A. 3. Department of Orthopedic Surgery, University of Virginia School of Medicine, Charlottesville, Virginia, U.S.A.. Electronic address: bcw4x@virginia.edu.
Abstract
PURPOSE: To evaluate the association of preoperative intra-articular hip injection with surgical site infection after hip arthroscopy. METHODS: A large administrative database was used to identify all patients undergoing hip arthroscopy from 2007 to 2015 within a single private insurer and from 2005 to 2012 within Medicare in the United States. Those that received an ipsilateral preoperative intra-articular hip injection were identified. The patients were then divided into the following groups based on the interval between preoperative injection and ipsilateral hip arthroscopy: (1) <3 months, (2) 3 to 6 months, and (3) 6 to 12 months. These groups were compared to a control group composed of patients with no history or a remote history (>12 months) of preoperative hip injection. Patients developing a surgical site infection within 6 months following hip arthroscopy were identified using International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes associated with infection. Groups were compared using a multivariate logistic regression analysis to control for age, gender, body mass index, smoking status, alcohol usage, and multiple medical comorbidities including diabetes mellitus, hemodialysis use, inflammatory arthritis, and peripheral vascular disease. RESULTS: In total, 19% of privately insured and 6% of Medicare patients received a hip injection within 12 months of hip arthroscopy. The overall infection rate in privately insured and Medicare patients was 1.19% and 1.10%, respectively. Preoperative hip injection within 3 months of surgery was associated with a significantly higher risk of postoperative infection versus controls (2.16%, odds ratio [OR] 6.1, P < .001, for privately insured group; 2.80%, OR 1.99, P = .037, for Medicare group). In contrast, preoperative hip injection given after more than 3 months of surgery was not associated with an increased risk of postoperative infection versus controls. CONCLUSIONS: Risk of infection after hip arthroscopy increased when preoperative intra-articular hip injections were given within 3 months of surgery. LEVEL OF EVIDENCE: Level III, retrospective comparative study.
PURPOSE: To evaluate the association of preoperative intra-articular hip injection with surgical site infection after hip arthroscopy. METHODS: A large administrative database was used to identify all patients undergoing hip arthroscopy from 2007 to 2015 within a single private insurer and from 2005 to 2012 within Medicare in the United States. Those that received an ipsilateral preoperative intra-articular hip injection were identified. The patients were then divided into the following groups based on the interval between preoperative injection and ipsilateral hip arthroscopy: (1) <3 months, (2) 3 to 6 months, and (3) 6 to 12 months. These groups were compared to a control group composed of patients with no history or a remote history (>12 months) of preoperative hip injection. Patients developing a surgical site infection within 6 months following hip arthroscopy were identified using International Classification of Diseases, Ninth Revision, and Current Procedural Terminology codes associated with infection. Groups were compared using a multivariate logistic regression analysis to control for age, gender, body mass index, smoking status, alcohol usage, and multiple medical comorbidities including diabetes mellitus, hemodialysis use, inflammatory arthritis, and peripheral vascular disease. RESULTS: In total, 19% of privately insured and 6% of Medicare patients received a hip injection within 12 months of hip arthroscopy. The overall infection rate in privately insured and Medicare patients was 1.19% and 1.10%, respectively. Preoperative hip injection within 3 months of surgery was associated with a significantly higher risk of postoperative infection versus controls (2.16%, odds ratio [OR] 6.1, P < .001, for privately insured group; 2.80%, OR 1.99, P = .037, for Medicare group). In contrast, preoperative hip injection given after more than 3 months of surgery was not associated with an increased risk of postoperative infection versus controls. CONCLUSIONS: Risk of infection after hip arthroscopy increased when preoperative intra-articular hip injections were given within 3 months of surgery. LEVEL OF EVIDENCE: Level III, retrospective comparative study.
Authors: Arvin B Kheterpal; Katherine M Bunnell; Jad S Husseini; Connie Y Chang; Scott D Martin; Adam C Zoga; Miriam A Bredella Journal: Skeletal Radiol Date: 2019-10-23 Impact factor: 2.199
Authors: John W Belk; Laura E Keeling; Matthew J Kraeutler; Michaela G Snow; Omer Mei-Dan; Anthony J Scillia; Eric C McCarty Journal: Orthop J Sports Med Date: 2021-08-17
Authors: Andreas Voss; Christian G Pfeifer; Maximilian Kerschbaum; Markus Rupp; Peter Angele; Volker Alt Journal: Knee Surg Sports Traumatol Arthrosc Date: 2021-03-23 Impact factor: 4.342